Switch to
More onapp

How to use scorecard? Learn more

Aarti Pharmalabs Ltd

AARTIPHARM
Health CareLabs & Life Sciences Services
SmallcapWith a market cap of ₹5,564 cr, stock is ranked 680
High RiskStock is 4.35x as volatile as Nifty
615.151.15 (+0.19%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CareLabs & Life Sciences Services
SmallcapWith a market cap of ₹5,564 cr, stock is ranked 680
High RiskStock is 4.35x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
25.65
PB RatioPB Ratio
3.57
Dividend YieldDiv. Yield
0.49%
Sector PESector PE
43.83
Sector PBSector PB
5.97
Sector Div YldSctr Div Yld
0.59%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Aarti Pharmalabs Limited is a manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), and xanthine derivatives situated in India. The Company delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, Bosutinib Intermediate and others. Its xanthine and allied products include theophylline anhydrous, aminophylline, etophylline, and theophylline.

Investor PresentationView older 

Sep 14, 2023

PDF
View Older Presentations

Financial TrendFinancial statements 

20212022202320240.001.201.951.860.000.120.190.22
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Appointment 
Announced OnMay 13, 2024

Aarti Pharmalabs Limited has informed the Exchange regarding Appointment of Mrs Nehal Garewal as Non- Executive Director of the company w.e.f. May 13, 2024. | Download

Aarti Pharmalabs Limited has informed the Exchange regarding Appointment of Mrs Nehal Garewal as Non- Executive Director of the company w.e.f. May 13, 2024. | Download

Appointment 
Announced OnMay 13, 2024

Aarti Pharmalabs Limited has informed the Exchange regarding Appointment of Mr Pradeep Thakur as Non- Executive Independent Director of the company w.e.f. May 13, 2024. | Download

Aarti Pharmalabs Limited has informed the Exchange regarding Appointment of Mr Pradeep Thakur as Non- Executive Independent Director of the company w.e.f. May 13, 2024. | Download

Cash Dividend 
Ex. DateFeb 16, 2024

Interim • Div/Share: ₹ 2

See all events